<DOC>
	<DOCNO>NCT01280695</DOCNO>
	<brief_summary>The purpose study assess safety tolerability MSDC-0602 evaluate reduction fast plasma glucose patient Type 2 diabetes .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Comparator- Placebo-Controlled , Multiple-Dose Study Evaluate Safety , Tolerability Efficacy Three Dose Levels MSDC-0602 Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Patients must meet follow inclusion criterion eligible enrollment study : 1 . Males females Type 2 diabetes ( fast plasma glucose ≥126 mg/dL screening , glycosylated hemoglobin [ HbA1c ] &gt; 7 ≤10 % , Insulin Cpeptide &gt; 1 ng/mL ) . Patients naïve diabetes therapy take metformin stable dose level period least 3 month prior screen visit ( dose limit ) . 2 . Between age 1875 year , inclusive . 3 . Females either postmenopausal ( least 12 month since last menses ) surgically sterilize ( bilateral tubal ligation hysterectomy ) . Menopausal status verify folliclestimulating hormone ( FSH ) test . If FSH level 40 mIU/mL , method birth control must use . Those bilateral tubal ligation must also use barrier method birth control . In addition , female must negative pregnancy test Screen Day 15 regardless childbearing potential . For postmenopausal woman , FSH level 40 mIU/mL serum pregnancy result indeterminant , subject assess pregnant . Males female partner childbearing potential must agree use adequate contraceptive method ( include condom , plus one form contraception ) engage sexual intercourse . 4 . Body Mass Index ( BMI ) ≥ 25 kg/m2 ≤ 45 kg/m2 ( inclusive ) . 5 . Willing able make screen visit clinic six visit 10 week period . 6 . Willing able sign inform consent document indicate understand purpose procedure require study willingness participate study . Subject 1 . Use TZDs diabetes medication metformin ( generic Glucophage® ) 3 month prior screen . 2 . History diabetic ketoacidosis hyperosmolar nonketotic coma . 3 . Fasting plasma glucose excess 240 mg/dl screen 4 . History heart failure ( include CHF ) previous cardiovascular event ( myocardial infarct , bypass surgery , PTCA ) within past 6 month prior screen . 5 . ALT and/or AST level equal exceed twice upper limit normal ; bilirubin level exceed 2 mg/dL ; serum creatinine &gt; 1.5 mg/dL men &gt; 1.4 mg/dL woman . 6 . History nephropathy , neuropathy , retinopathy within 6 month screen . 7 . Use glucocorticoid ( oral , injectible , intraarticular , chronic inhale ) weightloss drug within 3 month randomization . 8 . Current recurrent disease may affect action , absorption disposition study treatment , clinical laboratory assessment . 9 . Current history severe unstable disorder ( medical psychiatric ) require treatment may make patient unlikely complete study . 10 . Febrile illness within 5 day prior Visit 1 . 11 . Known history HIV , hepatitis B , hepatitis C. 12 . Clinically significant finding physical examination , include BP , pulse rate 12lead ECG . 13 . Blood pressure great 160/100 mmHg . Patients elevate BP ( &lt; 160/100 mmHg ) without current treatment allow discretion Principal Investigator ( PI ) primary care physician . Individuals hypertension must stabilize current treatment regimen least 6 week prior screen . 14 . Change BP lipidlowering medication within 6 week change dose metformin thyroid replacement within 3 month prior screen . 15 . Known suspected intolerance hypersensitivity study drug , closely related compound state ingredient . 16 . History alcohol drug abuse within 6 month Screening . 17 . Have participate investigational study receive investigational drug within 30 day 5 halflives ( whichever longer ) prior study drug administration . 18 . Blood donation 1 pint within 56 day screen . 19 . Plasmapheresis plasma donation within 30 day screen . 20 . Single 12lead ECG demonstrate QTcB &gt; 450 msec Screening . A single repeat ECG may do Investigator 's discretion . 21 . Any surgical medical condition may significantly alter absorption drug substance include , limited , follow : history major gastrointestinal tract surgery gastrectomy , gastroenterostomy , bowel resection , gastric bypass , gastric stapling , gastric banding , currently active inflammatory bowel syndrome . 22 . Evidence clinically relevant pathology could interfere study result put patient 's safety risk . 23 . Malignancy , include leukemia lymphoma ( include basal cell skin cancer ) within last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes</keyword>
	<keyword>High blood sugar</keyword>
	<keyword>Blood sugar</keyword>
	<keyword>Blood glucose</keyword>
	<keyword>Glucose</keyword>
</DOC>